143 related articles for article (PubMed ID: 38133707)
1. Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study.
de Wild SR; Koppert LB; de Munck L; Vrancken Peeters MTFD; Siesling S; Smidt ML; Simons JM
Breast Cancer Res Treat; 2024 Apr; 204(2):277-288. PubMed ID: 38133707
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases.
van Nijnatten TJ; Simons JM; Moossdorff M; de Munck L; Lobbes MB; van der Pol CC; Koppert LB; Luiten EJ; Smidt ML
Breast Cancer Res Treat; 2017 May; 163(1):159-166. PubMed ID: 28213782
[TBL] [Abstract][Full Text] [Related]
3. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
[TBL] [Abstract][Full Text] [Related]
4. Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer.
Moldoveanu D; Hoskin TL; Day CN; Schulze AK; Goetz MP; Boughey JC
Breast Cancer Res Treat; 2024 Feb; 203(3):419-428. PubMed ID: 37878154
[TBL] [Abstract][Full Text] [Related]
5. Nodal downstaging to ypN0 after neoadjuvant chemotherapy positively impacts on survival of cT4N+ GC/GEJ patients.
Wu L; Xing Z; Huang M; Yu H; Qin Y; Jin Q; Zhou Z; Chen J
J Surg Oncol; 2022 Dec; 126(8):1403-1412. PubMed ID: 36001384
[TBL] [Abstract][Full Text] [Related]
6. Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer.
van der Noordaa MEM; van Duijnhoven FH; Cuijpers FNE; van Werkhoven E; Wiersma TG; Elkhuizen PHM; Winter-Warnars G; Dezentje V; Sonke GS; Groen EJ; Stokkel M; Vrancken Peeters MTFD
Br J Surg; 2021 Jun; 108(6):667-674. PubMed ID: 34157085
[TBL] [Abstract][Full Text] [Related]
7. Long-term prognosis in breast cancer is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status.
Zetterlund L; Celebioglu F; Hatschek T; Frisell J; de Boniface J
Br J Surg; 2021 May; 108(5):583-589. PubMed ID: 34043772
[TBL] [Abstract][Full Text] [Related]
8. Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer.
Zhang GC; Zhang YF; Xu FP; Qian XK; Guo ZB; Ren CY; Yao M
Curr Oncol; 2013 Jun; 20(3):e180-92. PubMed ID: 23737688
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer.
Grova MM; Strassle PD; Navajas EE; Gallagher KK; Ollila DW; Downs-Canner SM; Spanheimer PM
Ann Surg Oncol; 2021 Apr; 28(4):2182-2190. PubMed ID: 32974693
[TBL] [Abstract][Full Text] [Related]
10. Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance).
Weiss A; Campbell J; Ballman KV; Sikov WM; Carey LA; Hwang ES; Poppe MM; Partridge AH; Ollila DW; Golshan M
Ann Surg Oncol; 2021 Oct; 28(11):5960-5971. PubMed ID: 33821344
[TBL] [Abstract][Full Text] [Related]
11. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
13. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ
Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer.
Wong SM; Almana N; Choi J; Hu J; Gagnon H; Natsuhara K; Shen AH; DeSantis S; Dominici L; Golshan M; Weiss A; Bellon J; Mittendorf EA; King TA
Ann Surg Oncol; 2019 Oct; 26(11):3502-3509. PubMed ID: 31228134
[TBL] [Abstract][Full Text] [Related]
16. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study.
Cabıoğlu N; Karanlık H; Yıldırım N; Müslümanoğlu M; Çakmak Karadeniz G; Trabulus Can D; Tükenmez M; Ersoy YE; Uras C; Zengel B; Emiroğlu S; Polat AK; Yeniay L; Özkurt E; Kara H; İbiş K; Aydıner A; Özmen V; İğci A
Eur J Surg Oncol; 2021 Oct; 47(10):2506-2514. PubMed ID: 34217580
[TBL] [Abstract][Full Text] [Related]
17. The nodal positivity rate in breast pCR patients with initially, clinically node-negative breast cancer after neoadjuvant systemic therapy: A systematic review and meta-analysis.
Ma L; Chen H; He J; Xie P; Gao P; Li Y; Zhang H; Fan Z
Front Oncol; 2023; 13():1167912. PubMed ID: 37064127
[TBL] [Abstract][Full Text] [Related]
18. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved.
Ikoma N; Estrella JS; Hofstetter W; Das P; Minsky BD; Ajani JA; Fournier KF; Mansfield P; Badgwell BD
Ann Surg Oncol; 2018 Jul; 25(7):2012-2017. PubMed ID: 29748883
[TBL] [Abstract][Full Text] [Related]
19. Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype.
Al-Hilli Z; Hoskin TL; Day CN; Habermann EB; Boughey JC
Ann Surg Oncol; 2018 Feb; 25(2):482-493. PubMed ID: 29181679
[TBL] [Abstract][Full Text] [Related]
20. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
